Laverdia®-CA1 (verdinexor tablets)
Laverdia®-CA1 is the first oral tablet FDA conditionally approved to treat lymphoma in dogs.
| Active(s)/Ingredient(s): | verdinexor |
| Pack size(s): | 50mg, 10mg, 2.5mg |
| Documents: | Client Information Sheet get_app Package insert get_app SDS get_app |
Important safety information
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Use only as Directed. It is a violation of Federal Law to use this product other than as directed in the labeling.
IMPORTANT SAFETY INFORMATION: For use in dogs only. Laverdia®-CA1(verdinexor) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH Laverdia®-CA1. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia®-CA1 or come into contact with the feces, urine, saliva, or vomit of treated dogs for 3 days following treatment. Laverdia®-CA1 can affect male fertility based on animal studies and studies in humans. Wear protective disposable chemotherapy resistant gloves when handling Laverdia®-CA1 to avoid direct exposure to moistened, broken or crushed tablets or biological waste from the treated dog (feces, urine, saliva, or vomit). Do not use in dogs that are pregnant, lactating or intended for breeding. Laverdia®-CA1 is a possible teratogen and can affect female and male fertility. Dogs should be frequently monitored for hematologic and serum chemistry abnormalities. The most commonly reported adverse reactions in dogs include anorexia, weight loss, vomiting, diarrhea, lethargy, polyuria, polydipsia, elevated liver enzymes and thrombocytopenia. Please see package insert or visit dechra-us.com for full prescribing information.